Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Роль глимепирида в комбинации с метформином в современной практике сахароснижающей терапии при сахарном диабете типа 2
Роль глимепирида в комбинации с метформином в современной практике сахароснижающей терапии при сахарном диабете типа 2
Жукова Л.А., Гуламов А.А., Кузнецов Е.В. Роль глимепирида в комбинации с метформином в современной практике сахароснижающей терапии при сахарном диабете типа 2. Consilium Medicum. 2015; 17 (4): 20–25.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье описано место препаратов сульфонилмочевины в современных рекомендациях по лечению пациентов с сахарным диабетом типа 2. Рассмотрены особенности механизма действия и фармакокинетики глимепирида и связанные с этим положительные отличия в эффективности терапии, частоте гипогликемических реакций, влиянии на массу, частоте побочных эффектов и осложнений лечения. Описаны результаты клинических исследований по изучению экстрапанкреатических эффектов глимепирида (влияние на синтез гликогена, показатели липидного обмена, ишемическое прекондиционирование, индекс инсулинорезистентности). Рассмотрена эффективность применения глимепирида (Амарила) в комбинации с метформином быстрого высвобождения и фиксированной комбинацией амарила с метформином (Амарил М).
Ключевые слова: сахарный диабет, глимепирид, Амарил, сахароснижающая терапия, прекондиционирование, механизм действия, гипогликемия.
Key words: diabetes mellitus, glimepiride, Amaryl, antihyperglycemic therapy, preconditioning, mechanism of action, hypoglycemia.
Ключевые слова: сахарный диабет, глимепирид, Амарил, сахароснижающая терапия, прекондиционирование, механизм действия, гипогликемия.
________________________________________________
Key words: diabetes mellitus, glimepiride, Amaryl, antihyperglycemic therapy, preconditioning, mechanism of action, hypoglycemia.
Полный текст
Список литературы
1. World Health Organisation: “The World Health Report 1998. Life in 21st Century – a Vision for ALL” Geneva: World Health Organisation, 1998.
2. IDF Diabetes Atlas, 6th ed. International Diabetes Federation, 2013. http://www.idf.org/diabetesatlas
3. Алгоритмы специализированной медицинской помощи больных сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой. 7-й выпуск. М., 2015. / Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nykh sakharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoi. 7-i vypusk. M., 2015. [in Russian]
4. Жукова Л.А., Гуламов А.А., Кузнецов Е.В. Роль процесса обучения больных сахарным диабетом типа 2 принципам самоконтроля и профилактики патологии нижних конечностей. Consilium Medicum. 2014; 16 (10): 121–5. / Zhukova L.A., Gulamov A.A., Kuznetsov E.V. Rol' protsessa obucheniia bol'nykh sakharnym diabetom tipa 2 printsipam samokontrolia i profilaktiki patologii nizhnikh konechnostei. Consilium Medicum. 2014; 16 (10): 121–5. [in Russian]
5. Hsueh WA, Law RE. Cardiovascular risk continuum: Implications of insulin resistance and diabetes. Am J Med 1998; 105 (1A): 4S–14S.
6. Недосугова Л.В. Препараты сульфонилмочевины в современной стратегии лечения сахарного диабета 2 типа. Сахарный диабет. 2011; 2: 99–109. / Nedosugova L.V. Preparaty sul'fonilmocheviny v sovremennoi strategii lecheniia sakharnogo diabeta 2 tipa. Sakharnyi diabet. 2011; 2: 99–109. [in Russian]
7. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22 (2): 233–40.
8. Дедов И.И. и др. Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии у больных сахарным диабетом 2 типа. Сахарный диабет. 2011; 4: 6–17. / Dedov I.I. i dr. Konsensus soveta ekspertov Rossiiskoi assotsiatsii endokrinologov po initsiatsii i intensifikatsii sakharosnizhaiushchei terapii u bol'nykh sakharnym diabetom 2 tipa. Sakharnyi diabet. 2011; 4: 6–17. [in Russian]
9. Muller G et al. The Molecular Mechanism of the Insulin-mimetic/sensitizing Activity of the Antidiabetic Sulfonylurea Drug Amaryl. Mol Med 2000; 6 (11): 907–33.
10. Руяткина Л.А., Сорокин М.Ю. Глимепирид в современной гипогликемизирующей терапии: безопасность и эффективность. Сахарный диабет. 2012; 2: 89–97. /
Ruiatkina L.A., Sorokin M.Iu. Glimepirid v sovremennoi gipoglikemiziruiushchei terapii: bezopasnost' i effektivnost'. Sakharnyi diabet. 2012; 2: 89–97. [in Russian]
11. Смирнова О.М. Принципы терапии впервые выявленного сахарного диабета 2 типа. Место Амарила (глимепирида): свойства, эффективность, безопасность. Сахарный диабет. 2009; 1: 43–7. / Smirnova O.M. Printsipy terapii vpervye vyiavlennogo sakharnogo diabeta 2 tipa. Mesto Amarila (glimepirida): svoistva, effektivnost', bezopasnost'. Sakharnyi diabet. 2009; 1: 43–7. [in Russian]
12. Максимова Н.В., Романцова Т.И. Оптимизация таблетированной сахароснижающей терапии с использованием глимепирида при сахарном диабете 2 типа. Сахарный диабет. 2010; 1: 50–4. / Maksimova N.V., Romantsova T.I. Optimizatsiia tabletirovannoi sakharosnizhaiushchei terapii s ispol'zovaniem glimepirida pri sakharnom diabete 2 tipa. Sakharnyi diabet. 2010; 1: 50–4. [in Russian]
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
14. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001; 17 (6): 467–73.
15. Schade DS, Jovanovic L, Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol 1998; 38 (7): 636–41.
16. Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care 1996; 19 (8): 849–56.
17. Charpentier G, Fleury F, Kabir M et al. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001; 18 (10): 828–34.
18. Muller G et al. Extrapancreatic effects of sulfonylureas – a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract 1995; 28 (Suppl.): 115–37.
19. Overkamp D, Volk A, Maerker E et al. Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabet Care 2002; 25 (11): 2065–73.
20. Xu DY, Zhao SP, Huang QX et al. Effects of Glimepiride on met-abolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Res Clin Pract 2010; 88 (1): 71–5.
21. Davis SN. The role of glimepiride in the effective management of type 2 diabetes. J Diabetes Complications 2004; 18 (6): 367–76.
22. Leibel B. An analysis of the University Group Diabetes Study Program: data results and conslusions. Can Med Assoc J 1971; 105 (3): 292–4.
23. Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother 1998; 32 (10): 1044–52.
24. Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res 1996; 28 (9): 426–9.
25. Nathan DM, Buse JB, Davidson MB et al. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32 (1): 193–203.
26. Holstein P et al. Glimepiride less hypoglycemia than glyburide. Diabetologia 2000; 43: A40.
27. Bugos C, Austin M, Atherton T, Viereck C. Long-term treatment of type 2 diabetes mellitus with glimepiride is weight neutral: a meta-analysis. Diabetes Res Clin Pract 2000; 50 (Suppl. 1): S47.
28. Scholz G, Schneider K, Knirsch W, Becker G. Efficacy and tolerability of glimepiride in daily practice: a non-interventional observational cohort study. Clin Drug Invest 2001; 21 (9): 597–604.
29. Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin 2006; 22 (4): 751–9.
30. Muller G, Wied S, Straub J, Jung C. Coordinated regulation of esterification and lipolysis by palmitate, H2O2 and the antidiabetic sulfonylurea drug, glimepiride, in rat adipocytes. Eur J Pharmacol 2008; 597 (1–3): 6–18.
31. Shakuto S, Sato Y, Ohshima K, Yaguchi M. Atheroprotective effects of a new sulfonylurea of the third generation, glimepiride. Diabet Complications 2001; 15 (Suppl. 1): 68.
32. Draeger KE, Wernicke-Panten K, Lomp HJ et al. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res 1996; 28 (9): 419–5.
33. Mocanu MM, Maddock HL, Baxter GF et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001; 103 (25): 3111–6.
34. Caulfield M, O’Brien K. Cardiovascular safety of oral antidiabetic agents: the insulin secretagogues. Clin Diabetes 2002; 20 (2): 81–4.
35. Klepzig H et al. Sulfonylureas and ischemic preconditioning: a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999; 20: 439–46.
36. Tsunekawa T et al. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care 2003; 26: 285–9.
37. Kishida K, Funahashi T, Shimomura I. Molecular mechanisms of diabetes and atherosclerosis: Role of adiponectin. Endocr Metab Immune Disord Drug Targets 2012 Jan 11. [Epub ahead of print].
38. Kim BH, Shin KH, Kim J et al. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. Clin Ther 2009; 31 (11): 2755–64.
39. Gu N, Kim BH, Rhim H et al. Comparison of the bioa-vailability and tolerability of fixed-dose combination glimepiride/metformin 2/500-mg tablets versus separate tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy Korean volunteers. Clin Ther 2010; 32 (7): 1408–18.
40. Shin KH, Kim SE, Yoon SH et al. Pharmacokinetic comparison of a new sustainedrelease formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover study. Clin Ther 2011; 33 (11): 1809–18.
41. Baik S et al. J Med Assoc Thai 2005; 88: S245.
42. Melikian C et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002; 24: 460–7.
43. Blonde L et al. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab 2003; 5: 424–31.
2. IDF Diabetes Atlas, 6th ed. International Diabetes Federation, 2013. http://www.idf.org/diabetesatlas
3. Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nykh sakharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoi. 7-i vypusk. M., 2015. [in Russian]
4. Zhukova L.A., Gulamov A.A., Kuznetsov E.V. Rol' protsessa obucheniia bol'nykh sakharnym diabetom tipa 2 printsipam samokontrolia i profilaktiki patologii nizhnikh konechnostei. Consilium Medicum. 2014; 16 (10): 121–5. [in Russian]
5. Hsueh WA, Law RE. Cardiovascular risk continuum: Implications of insulin resistance and diabetes. Am J Med 1998; 105 (1A): 4S–14S.
6. Nedosugova L.V. Preparaty sul'fonilmocheviny v sovremennoi strategii lecheniia sakharnogo diabeta 2 tipa. Sakharnyi diabet. 2011; 2: 99–109. [in Russian]
7. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22 (2): 233–40.
8. Dedov I.I. i dr. Konsensus soveta ekspertov Rossiiskoi assotsiatsii endokrinologov po initsiatsii i intensifikatsii sakharosnizhaiushchei terapii u bol'nykh sakharnym diabetom 2 tipa. Sakharnyi diabet. 2011; 4: 6–17. [in Russian]
9. Muller G et al. The Molecular Mechanism of the Insulin-mimetic/sensitizing Activity of the Antidiabetic Sulfonylurea Drug Amaryl. Mol Med 2000; 6 (11): 907–33.
10. Ruiatkina L.A., Sorokin M.Iu. Glimepirid v sovremennoi gipoglikemiziruiushchei terapii: bezopasnost' i effektivnost'. Sakharnyi diabet. 2012; 2: 89–97. [in Russian]
11. Smirnova O.M. Printsipy terapii vpervye vyiavlennogo sakharnogo diabeta 2 tipa. Mesto Amarila (glimepirida): svoistva, effektivnost', bezopasnost'. Sakharnyi diabet. 2009; 1: 43–7. [in Russian]
12. Maksimova N.V., Romantsova T.I. Optimizatsiia tabletirovannoi sakharosnizhaiushchei terapii s ispol'zovaniem glimepirida pri sakharnom diabete 2 tipa. Sakharnyi diabet. 2010; 1: 50–4. [in Russian]
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
14. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001; 17 (6): 467–73.
15. Schade DS, Jovanovic L, Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol 1998; 38 (7): 636–41.
16. Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care 1996; 19 (8): 849–56.
17. Charpentier G, Fleury F, Kabir M et al. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001; 18 (10): 828–34.
18. Muller G et al. Extrapancreatic effects of sulfonylureas – a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract 1995; 28 (Suppl.): 115–37.
19. Overkamp D, Volk A, Maerker E et al. Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabet Care 2002; 25 (11): 2065–73.
20. Xu DY, Zhao SP, Huang QX et al. Effects of Glimepiride on met-abolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Res Clin Pract 2010; 88 (1): 71–5.
21. Davis SN. The role of glimepiride in the effective management of type 2 diabetes. J Diabetes Complications 2004; 18 (6): 367–76.
22. Leibel B. An analysis of the University Group Diabetes Study Program: data results and conslusions. Can Med Assoc J 1971; 105 (3): 292–4.
23. Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother 1998; 32 (10): 1044–52.
24. Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res 1996; 28 (9): 426–9.
25. Nathan DM, Buse JB, Davidson MB et al. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32 (1): 193–203.
26. Holstein P et al. Glimepiride less hypoglycemia than glyburide. Diabetologia 2000; 43: A40.
27. Bugos C, Austin M, Atherton T, Viereck C. Long-term treatment of type 2 diabetes mellitus with glimepiride is weight neutral: a meta-analysis. Diabetes Res Clin Pract 2000; 50 (Suppl. 1): S47.
28. Scholz G, Schneider K, Knirsch W, Becker G. Efficacy and tolerability of glimepiride in daily practice: a non-interventional observational cohort study. Clin Drug Invest 2001; 21 (9): 597–604.
29. Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin 2006; 22 (4): 751–9.
30. Muller G, Wied S, Straub J, Jung C. Coordinated regulation of esterification and lipolysis by palmitate, H2O2 and the antidiabetic sulfonylurea drug, glimepiride, in rat adipocytes. Eur J Pharmacol 2008; 597 (1–3): 6–18.
31. Shakuto S, Sato Y, Ohshima K, Yaguchi M. Atheroprotective effects of a new sulfonylurea of the third generation, glimepiride. Diabet Complications 2001; 15 (Suppl. 1): 68.
32. Draeger KE, Wernicke-Panten K, Lomp HJ et al. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res 1996; 28 (9): 419–5.
33. Mocanu MM, Maddock HL, Baxter GF et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001; 103 (25): 3111–6.
34. Caulfield M, O’Brien K. Cardiovascular safety of oral antidiabetic agents: the insulin secretagogues. Clin Diabetes 2002; 20 (2): 81–4.
35. Klepzig H et al. Sulfonylureas and ischemic preconditioning: a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999; 20: 439–46.
36. Tsunekawa T et al. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care 2003; 26: 285–9.
37. Kishida K, Funahashi T, Shimomura I. Molecular mechanisms of diabetes and atherosclerosis: Role of adiponectin. Endocr Metab Immune Disord Drug Targets 2012 Jan 11. [Epub ahead of print].
38. Kim BH, Shin KH, Kim J et al. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. Clin Ther 2009; 31 (11): 2755–64.
39. Gu N, Kim BH, Rhim H et al. Comparison of the bioa-vailability and tolerability of fixed-dose combination glimepiride/metformin 2/500-mg tablets versus separate tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy Korean volunteers. Clin Ther 2010; 32 (7): 1408–18.
40. Shin KH, Kim SE, Yoon SH et al. Pharmacokinetic comparison of a new sustainedrelease formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover study. Clin Ther 2011; 33 (11): 1809–18.
41. Baik S et al. J Med Assoc Thai 2005; 88: S245.
42. Melikian C et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002; 24: 460–7.
43. Blonde L et al. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab 2003; 5: 424–31.
2. IDF Diabetes Atlas, 6th ed. International Diabetes Federation, 2013. http://www.idf.org/diabetesatlas
3. Алгоритмы специализированной медицинской помощи больных сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой. 7-й выпуск. М., 2015. / Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nykh sakharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoi. 7-i vypusk. M., 2015. [in Russian]
4. Жукова Л.А., Гуламов А.А., Кузнецов Е.В. Роль процесса обучения больных сахарным диабетом типа 2 принципам самоконтроля и профилактики патологии нижних конечностей. Consilium Medicum. 2014; 16 (10): 121–5. / Zhukova L.A., Gulamov A.A., Kuznetsov E.V. Rol' protsessa obucheniia bol'nykh sakharnym diabetom tipa 2 printsipam samokontrolia i profilaktiki patologii nizhnikh konechnostei. Consilium Medicum. 2014; 16 (10): 121–5. [in Russian]
5. Hsueh WA, Law RE. Cardiovascular risk continuum: Implications of insulin resistance and diabetes. Am J Med 1998; 105 (1A): 4S–14S.
6. Недосугова Л.В. Препараты сульфонилмочевины в современной стратегии лечения сахарного диабета 2 типа. Сахарный диабет. 2011; 2: 99–109. / Nedosugova L.V. Preparaty sul'fonilmocheviny v sovremennoi strategii lecheniia sakharnogo diabeta 2 tipa. Sakharnyi diabet. 2011; 2: 99–109. [in Russian]
7. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22 (2): 233–40.
8. Дедов И.И. и др. Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии у больных сахарным диабетом 2 типа. Сахарный диабет. 2011; 4: 6–17. / Dedov I.I. i dr. Konsensus soveta ekspertov Rossiiskoi assotsiatsii endokrinologov po initsiatsii i intensifikatsii sakharosnizhaiushchei terapii u bol'nykh sakharnym diabetom 2 tipa. Sakharnyi diabet. 2011; 4: 6–17. [in Russian]
9. Muller G et al. The Molecular Mechanism of the Insulin-mimetic/sensitizing Activity of the Antidiabetic Sulfonylurea Drug Amaryl. Mol Med 2000; 6 (11): 907–33.
10. Руяткина Л.А., Сорокин М.Ю. Глимепирид в современной гипогликемизирующей терапии: безопасность и эффективность. Сахарный диабет. 2012; 2: 89–97. /
Ruiatkina L.A., Sorokin M.Iu. Glimepirid v sovremennoi gipoglikemiziruiushchei terapii: bezopasnost' i effektivnost'. Sakharnyi diabet. 2012; 2: 89–97. [in Russian]
11. Смирнова О.М. Принципы терапии впервые выявленного сахарного диабета 2 типа. Место Амарила (глимепирида): свойства, эффективность, безопасность. Сахарный диабет. 2009; 1: 43–7. / Smirnova O.M. Printsipy terapii vpervye vyiavlennogo sakharnogo diabeta 2 tipa. Mesto Amarila (glimepirida): svoistva, effektivnost', bezopasnost'. Sakharnyi diabet. 2009; 1: 43–7. [in Russian]
12. Максимова Н.В., Романцова Т.И. Оптимизация таблетированной сахароснижающей терапии с использованием глимепирида при сахарном диабете 2 типа. Сахарный диабет. 2010; 1: 50–4. / Maksimova N.V., Romantsova T.I. Optimizatsiia tabletirovannoi sakharosnizhaiushchei terapii s ispol'zovaniem glimepirida pri sakharnom diabete 2 tipa. Sakharnyi diabet. 2010; 1: 50–4. [in Russian]
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
14. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001; 17 (6): 467–73.
15. Schade DS, Jovanovic L, Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol 1998; 38 (7): 636–41.
16. Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care 1996; 19 (8): 849–56.
17. Charpentier G, Fleury F, Kabir M et al. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001; 18 (10): 828–34.
18. Muller G et al. Extrapancreatic effects of sulfonylureas – a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract 1995; 28 (Suppl.): 115–37.
19. Overkamp D, Volk A, Maerker E et al. Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabet Care 2002; 25 (11): 2065–73.
20. Xu DY, Zhao SP, Huang QX et al. Effects of Glimepiride on met-abolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Res Clin Pract 2010; 88 (1): 71–5.
21. Davis SN. The role of glimepiride in the effective management of type 2 diabetes. J Diabetes Complications 2004; 18 (6): 367–76.
22. Leibel B. An analysis of the University Group Diabetes Study Program: data results and conslusions. Can Med Assoc J 1971; 105 (3): 292–4.
23. Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother 1998; 32 (10): 1044–52.
24. Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res 1996; 28 (9): 426–9.
25. Nathan DM, Buse JB, Davidson MB et al. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32 (1): 193–203.
26. Holstein P et al. Glimepiride less hypoglycemia than glyburide. Diabetologia 2000; 43: A40.
27. Bugos C, Austin M, Atherton T, Viereck C. Long-term treatment of type 2 diabetes mellitus with glimepiride is weight neutral: a meta-analysis. Diabetes Res Clin Pract 2000; 50 (Suppl. 1): S47.
28. Scholz G, Schneider K, Knirsch W, Becker G. Efficacy and tolerability of glimepiride in daily practice: a non-interventional observational cohort study. Clin Drug Invest 2001; 21 (9): 597–604.
29. Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin 2006; 22 (4): 751–9.
30. Muller G, Wied S, Straub J, Jung C. Coordinated regulation of esterification and lipolysis by palmitate, H2O2 and the antidiabetic sulfonylurea drug, glimepiride, in rat adipocytes. Eur J Pharmacol 2008; 597 (1–3): 6–18.
31. Shakuto S, Sato Y, Ohshima K, Yaguchi M. Atheroprotective effects of a new sulfonylurea of the third generation, glimepiride. Diabet Complications 2001; 15 (Suppl. 1): 68.
32. Draeger KE, Wernicke-Panten K, Lomp HJ et al. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res 1996; 28 (9): 419–5.
33. Mocanu MM, Maddock HL, Baxter GF et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001; 103 (25): 3111–6.
34. Caulfield M, O’Brien K. Cardiovascular safety of oral antidiabetic agents: the insulin secretagogues. Clin Diabetes 2002; 20 (2): 81–4.
35. Klepzig H et al. Sulfonylureas and ischemic preconditioning: a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999; 20: 439–46.
36. Tsunekawa T et al. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care 2003; 26: 285–9.
37. Kishida K, Funahashi T, Shimomura I. Molecular mechanisms of diabetes and atherosclerosis: Role of adiponectin. Endocr Metab Immune Disord Drug Targets 2012 Jan 11. [Epub ahead of print].
38. Kim BH, Shin KH, Kim J et al. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. Clin Ther 2009; 31 (11): 2755–64.
39. Gu N, Kim BH, Rhim H et al. Comparison of the bioa-vailability and tolerability of fixed-dose combination glimepiride/metformin 2/500-mg tablets versus separate tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy Korean volunteers. Clin Ther 2010; 32 (7): 1408–18.
40. Shin KH, Kim SE, Yoon SH et al. Pharmacokinetic comparison of a new sustainedrelease formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover study. Clin Ther 2011; 33 (11): 1809–18.
41. Baik S et al. J Med Assoc Thai 2005; 88: S245.
42. Melikian C et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002; 24: 460–7.
43. Blonde L et al. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab 2003; 5: 424–31.
________________________________________________
2. IDF Diabetes Atlas, 6th ed. International Diabetes Federation, 2013. http://www.idf.org/diabetesatlas
3. Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nykh sakharnym diabetom. Pod red. I.I.Dedova, M.V.Shestakovoi. 7-i vypusk. M., 2015. [in Russian]
4. Zhukova L.A., Gulamov A.A., Kuznetsov E.V. Rol' protsessa obucheniia bol'nykh sakharnym diabetom tipa 2 printsipam samokontrolia i profilaktiki patologii nizhnikh konechnostei. Consilium Medicum. 2014; 16 (10): 121–5. [in Russian]
5. Hsueh WA, Law RE. Cardiovascular risk continuum: Implications of insulin resistance and diabetes. Am J Med 1998; 105 (1A): 4S–14S.
6. Nedosugova L.V. Preparaty sul'fonilmocheviny v sovremennoi strategii lecheniia sakharnogo diabeta 2 tipa. Sakharnyi diabet. 2011; 2: 99–109. [in Russian]
7. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22 (2): 233–40.
8. Dedov I.I. i dr. Konsensus soveta ekspertov Rossiiskoi assotsiatsii endokrinologov po initsiatsii i intensifikatsii sakharosnizhaiushchei terapii u bol'nykh sakharnym diabetom 2 tipa. Sakharnyi diabet. 2011; 4: 6–17. [in Russian]
9. Muller G et al. The Molecular Mechanism of the Insulin-mimetic/sensitizing Activity of the Antidiabetic Sulfonylurea Drug Amaryl. Mol Med 2000; 6 (11): 907–33.
10. Ruiatkina L.A., Sorokin M.Iu. Glimepirid v sovremennoi gipoglikemiziruiushchei terapii: bezopasnost' i effektivnost'. Sakharnyi diabet. 2012; 2: 89–97. [in Russian]
11. Smirnova O.M. Printsipy terapii vpervye vyiavlennogo sakharnogo diabeta 2 tipa. Mesto Amarila (glimepirida): svoistva, effektivnost', bezopasnost'. Sakharnyi diabet. 2009; 1: 43–7. [in Russian]
12. Maksimova N.V., Romantsova T.I. Optimizatsiia tabletirovannoi sakharosnizhaiushchei terapii s ispol'zovaniem glimepirida pri sakharnom diabete 2 tipa. Sakharnyi diabet. 2010; 1: 50–4. [in Russian]
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
14. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001; 17 (6): 467–73.
15. Schade DS, Jovanovic L, Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol 1998; 38 (7): 636–41.
16. Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care 1996; 19 (8): 849–56.
17. Charpentier G, Fleury F, Kabir M et al. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001; 18 (10): 828–34.
18. Muller G et al. Extrapancreatic effects of sulfonylureas – a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract 1995; 28 (Suppl.): 115–37.
19. Overkamp D, Volk A, Maerker E et al. Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabet Care 2002; 25 (11): 2065–73.
20. Xu DY, Zhao SP, Huang QX et al. Effects of Glimepiride on met-abolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Res Clin Pract 2010; 88 (1): 71–5.
21. Davis SN. The role of glimepiride in the effective management of type 2 diabetes. J Diabetes Complications 2004; 18 (6): 367–76.
22. Leibel B. An analysis of the University Group Diabetes Study Program: data results and conslusions. Can Med Assoc J 1971; 105 (3): 292–4.
23. Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother 1998; 32 (10): 1044–52.
24. Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res 1996; 28 (9): 426–9.
25. Nathan DM, Buse JB, Davidson MB et al. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32 (1): 193–203.
26. Holstein P et al. Glimepiride less hypoglycemia than glyburide. Diabetologia 2000; 43: A40.
27. Bugos C, Austin M, Atherton T, Viereck C. Long-term treatment of type 2 diabetes mellitus with glimepiride is weight neutral: a meta-analysis. Diabetes Res Clin Pract 2000; 50 (Suppl. 1): S47.
28. Scholz G, Schneider K, Knirsch W, Becker G. Efficacy and tolerability of glimepiride in daily practice: a non-interventional observational cohort study. Clin Drug Invest 2001; 21 (9): 597–604.
29. Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin 2006; 22 (4): 751–9.
30. Muller G, Wied S, Straub J, Jung C. Coordinated regulation of esterification and lipolysis by palmitate, H2O2 and the antidiabetic sulfonylurea drug, glimepiride, in rat adipocytes. Eur J Pharmacol 2008; 597 (1–3): 6–18.
31. Shakuto S, Sato Y, Ohshima K, Yaguchi M. Atheroprotective effects of a new sulfonylurea of the third generation, glimepiride. Diabet Complications 2001; 15 (Suppl. 1): 68.
32. Draeger KE, Wernicke-Panten K, Lomp HJ et al. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res 1996; 28 (9): 419–5.
33. Mocanu MM, Maddock HL, Baxter GF et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001; 103 (25): 3111–6.
34. Caulfield M, O’Brien K. Cardiovascular safety of oral antidiabetic agents: the insulin secretagogues. Clin Diabetes 2002; 20 (2): 81–4.
35. Klepzig H et al. Sulfonylureas and ischemic preconditioning: a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999; 20: 439–46.
36. Tsunekawa T et al. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care 2003; 26: 285–9.
37. Kishida K, Funahashi T, Shimomura I. Molecular mechanisms of diabetes and atherosclerosis: Role of adiponectin. Endocr Metab Immune Disord Drug Targets 2012 Jan 11. [Epub ahead of print].
38. Kim BH, Shin KH, Kim J et al. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. Clin Ther 2009; 31 (11): 2755–64.
39. Gu N, Kim BH, Rhim H et al. Comparison of the bioa-vailability and tolerability of fixed-dose combination glimepiride/metformin 2/500-mg tablets versus separate tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy Korean volunteers. Clin Ther 2010; 32 (7): 1408–18.
40. Shin KH, Kim SE, Yoon SH et al. Pharmacokinetic comparison of a new sustainedrelease formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover study. Clin Ther 2011; 33 (11): 1809–18.
41. Baik S et al. J Med Assoc Thai 2005; 88: S245.
42. Melikian C et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002; 24: 460–7.
43. Blonde L et al. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab 2003; 5: 424–31.
Авторы
Л.А.Жукова*, А.А.Гуламов, Е.В.Кузнецов
ГБОУ ВПО Курский государственный медицинский университет Минздрава России. 305041, Россия, Курск, ул. Карла Маркса, д. 3
*profzhukova@mail.ru
Kursk State Medical University of the Ministry of Health of the Russian Federation. 305041, Russian Federation, Kursk, ul. Karla Marksa, d. 3.
*profzhukova@mail.ru
ГБОУ ВПО Курский государственный медицинский университет Минздрава России. 305041, Россия, Курск, ул. Карла Маркса, д. 3
*profzhukova@mail.ru
________________________________________________
Kursk State Medical University of the Ministry of Health of the Russian Federation. 305041, Russian Federation, Kursk, ul. Karla Marksa, d. 3.
*profzhukova@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.